Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
about
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugsThe PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Acalabrutinib (ACP-196): a selective second-generation BTK inhibitorThe therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsRegulation of PI3K effector signalling in cancer by the phosphoinositide phosphatasesActivating Akt1 mutations alter DNA double strand break repair and radiosensitivity.Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Future therapeutic targets in rheumatoid arthritis?Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemiaThe curious origins of angioimmunoblastic T-cell lymphomaINPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathwaysIdelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Drugging PI3K in cancer: refining targets and therapeutic strategiesPharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Defective phosphoinositide metabolism in autism.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemiaSafety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.[Guidelines for vaccination of immunocompromised individuals].Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.Characterization of the novel indolylmaleimides' PDA-66 and PDA-377 effect on canine lymphoma cells.Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin.Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones.Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.
P2860
Q26766039-BE1771EB-5532-4697-B5B5-4C85FA09B36AQ26766054-11613DB6-CF5C-4D94-ACE7-7987ADEA4DE2Q27320446-E7046F78-21B4-4C6E-8DA5-1CB896F342E6Q28066316-E57230E3-9906-42D9-BEA9-9FD1487A99E7Q28070264-D878F780-A304-4EFA-BAFD-AE6860D23033Q29248612-8C2BF2FF-D4A4-425C-8B23-DFBCB87A8816Q30838969-827E90E1-E1EE-4585-87A7-C975743060BFQ33424543-4C47749E-5F72-42EE-AE52-405231E490DFQ33433009-73F75E7E-A4CE-44DF-B053-60F856209ADAQ33442621-FDF40CA8-2DC6-444D-9083-02F2F356F71BQ33607950-5E0867CF-02BB-485A-A8FD-E487501B67A2Q33841419-07C05BF7-F932-4166-9BF0-83674EB43744Q33873323-3DA76B14-1AAF-4912-A0C1-356AC728F50AQ33877993-18F2125F-8950-45F1-A24A-4D04ED47DCD7Q35844628-32029DA5-4D94-466D-B822-A8888B2BC741Q36274292-D6E8B8CD-9B89-4CD3-9194-579B3F9F780BQ36689108-2128A8D9-5FFA-49E9-9AC1-3A3237C108EFQ37725415-EC293861-5044-40E9-9002-4D500CF209E4Q38539217-7B5F15F7-6846-4E62-B04B-83AF632FBD4DQ38544216-266FB8CE-E319-4AA9-ADE7-EF61E2A39197Q38646974-DC01C2EA-6326-4BAB-9678-50B41A82EB0BQ38783064-1A6612BA-B98B-40D9-B699-3920E4585DBEQ38819164-09905868-AE23-46A4-940C-39279A22BEDDQ38819975-BDD5AB26-8A08-46A3-BB2B-D79005640ED1Q38885442-40EDCF83-B2F4-49A2-92CA-3BF321CC9709Q38984735-47CA6C7B-400C-4537-804A-B9D095E65865Q39065374-81CDA0E9-6CA0-4E15-B38B-DA6B923C62ACQ39226787-356B2DAF-BEDB-42EB-8CED-A5989D4D9F18Q39227773-19935AA6-F0C0-4D34-8434-F51AB04AA07CQ39472422-72EFCB08-EC57-472A-8896-F2FD0FA890BDQ39933783-CB118BB2-0862-4694-973D-25707FF30517Q40401733-EF59E1DE-17B7-4F96-A465-B1BFEF878B64Q40600058-E17AD09E-E68B-43C4-A868-0902BE89F77EQ40821648-C86699C2-2A05-438C-9725-0723EA09A473Q41610540-4AA5D949-DD0D-471B-B1FF-7EB7DBB471BFQ46558435-BC044C3C-676B-478F-8D2A-B441ACBDF000Q47106685-7AF96002-21B5-4643-AD83-94294CD7EDDEQ47137924-1C932017-E026-4CED-901A-310C2B6026A5Q47153501-EFE53A40-E3FB-4B50-9325-37BB817647E6Q47300115-BE318CA0-2F52-4893-A2D6-60B63C189FA1
P2860
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@ast
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@en
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@nl
type
label
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@ast
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@en
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@nl
prefLabel
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@ast
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@en
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@nl
P2093
P2860
P3181
P1476
Idelalisib: First-in-Class PI3 ...... kemia, and Follicular Lymphoma
@en
P2093
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-14-2034
P407
P577
2015-04-01T00:00:00Z